The UK and US have finalized a significant commercial pact that will maintain no import taxes on British medicine exports being sold in the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the public health system. This pledge secures that import taxes on these vital products will stay at zero for a timeframe of the next three years.
This agreement is in response to recent statements to significantly raise duties on patented pharmaceutical imports, with potential rates mentioned up to double the cost.
"This arrangement with the UK bolsters the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. drug exports," a statement said.
Economic Impact
Medicines represent one of the UK's most significant export categories to the America, which is easily the largest buyer for large British pharmaceutical firms.
Statistics indicate that in the 12 months prior to the third quarter, the UK shipped medicines valued at billions to the US. This value made up 17.4% of total UK exports in that period.
"This deal secures jobs, boosts funding and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Specific UK Commitments
The deal entails several notable commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must pay back to the NHS to control costs will be restricted at 15%. Last year, repayments were more than twenty percent.
Industry Background
This agreement comes amid a protracted tension between the drug companies and the ministers over medicine costs and regulatory access.
This friction were heightened by arguments that American patients were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while substantial funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had shrunk as a percentage of its overall budget over the past decade.
